CRISPR enzymes and systems

US12305204B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• Massachusetts Institute of Technology · US

Inventors

• Feng Zhang · Cambridge, US
• David A. Scott · Cambridge, US
• Winston X. Yan · Brookline, US
• Sourav Roy Choudhury · Newton, US
• Matthias Heidenreich · Cambridge, US

Key dates

• Filing date: Oct 17, 2023
• Grant date: May 20, 2025
• Expiry date: Oct 17, 2043

Classification

• Technology area (CPC G): Physics
• CPC primary: G16B30/00
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

In one aspect, embodiments disclosed herein are directed to engineered CRISPRCas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wild type. In certain example embodiments, the CRISPR-Cas effector protein is a Type II effector protein. In certain other example embodiments, the Type V effector protein is Cas9 or an orthologs or engineered variant thereof. Example Cas9 proteins suitable for use in the embodiments disclosed herein are discussed in further detail below.